Hunan Cancer Hospital
Clinical Trials
47
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (31 trials with phase data)• Click on a phase to view related trials
Immunonutrition Reduces Acute Esophagitis After Thoracic Radiotherapy in Lung Cancer
- Conditions
- Non Small Cell Lung CancerSmall Cell Lung Cancer
- First Posted Date
- 2025-02-21
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 121
- Registration Number
- NCT06840704
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
LDRT and Chemoimmunotherapy in NPC With Liver Metastasis
- Conditions
- Nasopharyngeal Cancinoma (NPC)
- First Posted Date
- 2025-01-22
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 26
- Registration Number
- NCT06788002
- Locations
- 🇨🇳
Huai Liu, Changsha, Hunan, China
🇨🇳Hui Wang, Changsha, Hunan, China
Bone Marrow Protective Effect of Trilaciclib in Postoperative CCRT for LA-HNSCC
- Conditions
- Head and Neck Cancer Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2024-12-31
- Last Posted Date
- 2024-12-31
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06752798
- Locations
- 🇨🇳
Hunan Cancer hospital, Changsha, Hunan, China
Real-world First-line Serplulimab-based Immunochemotherapy for Extensive-stage Small Cell Lung Cancer
- Conditions
- Extensive-stage Small Cell Lung Cancer (ES-SCLC)
- First Posted Date
- 2024-12-27
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 600
- Registration Number
- NCT06748495
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
Anlotinib-based Combination Therapy in Patients with Hormone Receptor-positive（HR+） Metastatic Breast Cancer(MBC) .
- Conditions
- HR+ Breast Cancer
- First Posted Date
- 2024-12-16
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT06734533
- Locations
- 🇨🇳
Hunan Provincial Tumor Hospital, Changsha, Hunan, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 10
- Next
News
SHR-A1921 Shows Promise in Platinum-Resistant Ovarian Cancer
• SHR-A1921, an antibody-drug conjugate, demonstrated a 42.3% overall response rate in platinum-resistant ovarian cancer patients at a 3.0 mg/kg dose. • The disease control rate reached 100% in patients treated with SHR-A1921 at 3.0 mg/kg, with a median duration of response of 9.9 months. • Manageable safety profiles were observed across both 3.0 mg/kg and 2.0 mg/kg dosing regimens of SHR-A1921 in heavily pretreated patients. • A phase 3 trial is underway to compare SHR-A1921 with chemotherapy in platinum-resistant epithelial ovarian cancer.